Ignite Creation Date:
2024-05-05 @ 4:56 PM
Last Modification Date:
2024-10-26 @ 9:26 AM
Study NCT ID:
NCT00354367
Status:
WITHDRAWN
Last Update Posted:
2012-05-28
First Post:
2006-07-18
Brief Title:
Evaluate Efficacy of Certolizumab in Crohns Patients With Draining Fistulas
Sponsor:
UCB Pharma
Organization:
UCB Pharma
Study Overview
Official Title:
A Phase IIIB Multicenter Open Label Randomized Clinical Trial Evaluating Efficacy of Certolizumab Pegol a PEGylated Fab Fragment of Humanized Antibody to Tumor Necrosis Factor TNF in Crohns Disease Patients With Draining Fistulas
Status:
WITHDRAWN
Status Verified Date:
2012-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To investigate the clinical efficacy of certolizumab pegol for fistula closure in Crohns disease subjects with active draining fistulas
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None